Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes

The Pharmacogenomics Journal volume 12, pages 255–259 (2012)Cite this article

Subjects

Abstract

The aim of this study is to evaluate whether the quantitative prescription of risperidone (dosage) is related to the patient's metabolic status. Metabolic status was defined in terms of the most relevant polymorphisms of CYP2D6 (*3, *4, *5, *6 and *1xN), CYP3A5 (*3A) and ABCB1 (G2677T) determined a posteriori and blinded to the clinicians. This prospective and observational study includes a cohort of 151 Caucasian psychiatric patients treated with risperidone. Significant differences (Kruskal–Wallis test p=0.01) among the doses administered were observed to correlate (Spearman's r=1, p=0.02) with the different CYP2D6 groups. Poor metabolizers received the lowest doses and ultra rapid metabolizers the highest. No significant correlations were observed with regard to CYP3A5 and ABCB1. We find that, despite not knowing patients' metabolic status, clinicians modify risperidone dosage in order to obtain the best therapeutic option.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42.

    CAS  PubMed  Google Scholar 

  2. Yasui-Furukori N, Hidestrand M, Spina E, Facciolá G, Scordo MG, Tybring G . Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29: 1263–1268.

    CAS  PubMed  Google Scholar 

  3. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J . Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134–1141.

    CAS  PubMed  Google Scholar 

  4. Fang J, Bourin M, Baker GB . Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 147–151.

    Article  CAS  PubMed  Google Scholar 

  5. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K . Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20: 380–384.

    Article  CAS  PubMed  Google Scholar 

  6. Kang RH, Jung SM, Kim KA, Lee DK, Cho HK, Jung BJ et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J Clin Psychopharmacol 2009; 29: 272–277.

    Article  CAS  PubMed  Google Scholar 

  7. Marzolini C, Paus E, Buclin T, Kim RB . Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33.

    Article  CAS  PubMed  Google Scholar 

  8. Boulton DW, DeVane CL, Liston HL, Markowitz JS . In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002; 71: 163–169.

    Article  CAS  PubMed  Google Scholar 

  9. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL . The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 2004; 7: 415–419.

    Article  CAS  PubMed  Google Scholar 

  10. Rodríguez-Antona C, Gurwitz D, de Leon J, Llerena A, Kirchheiner J, de Mesa EG et al. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 2009; 10: 685–699.

    Article  PubMed  Google Scholar 

  11. Gunes A, Spina E, Dahl ML, Scordo MG . ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30: 628–633.

    Article  CAS  PubMed  Google Scholar 

  12. Crescenti A, Mas S, Gassó P, Parellada E, Bernardo M, Lafuente A . CYP2D6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving AP therapy. Clin Exp Pharmacol Physiol 2008; 35: 807–811.

    Article  CAS  PubMed  Google Scholar 

  13. Gasso P, Mas S, Bernardo M, lvarez S, Parelllada E, Lafuente A . A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. The Pharmacogenomics J 2009; 9: 404–410.

    Article  CAS  PubMed  Google Scholar 

  14. Gasso P, Mas S, Crescenti A, Bernardo M, Parellada E, Lafuente A . Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. Psychiatry Res 2010; 175: 173–175.

    Article  CAS  PubMed  Google Scholar 

  15. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P et al. Polymorphism of Dopamine D2 receptor (TaqIA, TaqIB, and -141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008; 161: 131–141.

    Article  CAS  PubMed  Google Scholar 

  16. Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gassó P et al. The polymorphism of the Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotic. Schizophrenia Res 2007; 90: 115–122.

    Article  Google Scholar 

  17. Crescenti A, Mas S, Gasso P, Baiget M, Bernardo M, Lafuente A . Simultaneous genotyping of CYP2D6 *3,*4,*5 and *6 polymorphisms in a spanish population through multiplex long-PCR and minisequencing multiplex sinfle base extension (SBE) analysis. Clin Exp Pharmacol Physiol 2007; 34: 992–997.

    Article  CAS  PubMed  Google Scholar 

  18. de Leon J, Sandson NB, Cozza KL . A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics. Psychosomatics 2008; 49: 347–361.

    Article  CAS  PubMed  Google Scholar 

  19. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotic: the contribution of allelic variations to the phenotype drug response. Mol Psychiatry 2001; 9: 442–473.

    Article  Google Scholar 

  20. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH, Wedlund PJ . The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15–27.

    Article  CAS  PubMed  Google Scholar 

  21. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40: 630–639.

    Article  PubMed  Google Scholar 

  22. Farmer KC . Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074–1090.

    Article  CAS  PubMed  Google Scholar 

  23. Sjöqvist F, Eliasson E . The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81: 899–902.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

PG was supported by a ‘Sara Borrell’ contract (CD09/00296) from the Spanish Ministry of Health, Instituto de Salud Carlos III (FIS, Fondo de Investigacion Sanitaria). We thank Rosa Abellana PhD. (Dpt Public Health, University of Barcelona, Casanova 143, E-08036 Barcelona, Spain) for statistical assessment, and the Language Advisory Service at the University of Barcelona, Spain for manuscript revision. Funding: This study was supported by the Spanish Ministry of Health, Instituto de Salud Carlos III (FIS, Fondo de Investigacion Sanitaria P1060182U-2006), the Catalonia Ministry of Innovation, Universities and Enterprise (DIUE, 2009SGR1295, 2009SGR1501) and SENY foundation.

Author information

Authors and Affiliations

  1. Department of Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, Barcelona, Spain

    S Mas, P Gassò, S Álvarez & A Lafuente

  2. Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

    S Mas, P Gassò, S Álvarez, E Parellada, M Bernardo & A Lafuente

  3. Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain

    S Mas, P Gassò, S Álvarez, E Parellada, M Bernardo & A Lafuente

  4. Psychiatry service, Hospital Clinic de Barcelona, Barcelona, Spain

    E Parellada & M Bernardo

  5. Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Barcelona, Spain

    M Bernardo

Authors
  1. S Mas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Gassò
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Parellada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Bernardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Lafuente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Lafuente.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mas, S., Gassò, P., Álvarez, S. et al. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J 12, 255–259 (2012). https://doi.org/10.1038/tpj.2010.91

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.91

Keywords

This article is cited by

Search

Advanced search

Quick links